ABSTRACT
Objectives The multifaceted manifestation of COVID-19 requires longitudinal characterization of symptoms, to aid with screening and disease management.
Methods Phone interviews and follow-ups were completed with 112 mostly mild COVID-19 RT-PCR-positive adult patients, over a six-months period.
Results More than one symptom at disease onset was experienced by ∼70% of the patients. About 40% of the patients experienced fever, dry cough, headache, or muscle ache as the first symptom. Fatigue, if reported, usually was the first to appear. Smell and taste changes were experienced 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± SD) after disease onset and emerged as first symptom in 15% and 18% of patients, respectively. Fever had the shortest duration (5.8 ± 8.6 days), and taste and smell changes were the longest-lasting symptoms (17.2 ± 17.6 and 18.9 ± 19.7 days, durations censored at 60 days). Longer smell recovery correlated with smell change severity. Cough, taste change and smell change persisted after negative RT-PCR tests (in 20%, 26% and 29% of the patients in total). At six-months follow-up, 46% of the patients had at least one unresolved symptom, most commonly fatigue (21%), chemosensory changes (14%) or breath difficulty (9%).
Conclusions More than one symptom typically occurred at disease onset. Chemosensory changes and cough persisted after negative RT-PCR in a quarter of the patients. Almost half of the patients reported at least one unresolved symptom at six-months follow up, mainly fatigue, smell changes and breath difficulty. Our findings highlight the prevalence of long-lasting effects of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MYN is supported by Israel Science Foundation (ISF) grant #1129/19. HK is a recipient of the Uri Zehavi Scholarship. This work was supported in part by Edmond de Rothschild foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with Helsinki committee and the required ethics approval was granted (reference number HMO-0236-20).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Follow up of patients extended to 6 months, analyses, figures, supplemental and conclusions updated accordingly.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
LIST OF ABBREVIATIONS
- CDC
- Centers for Disease Control and Prevention
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- SD
- Standard Deviation
- GCCR
- Global Consortium for Chemosensory Research
- RT-PCR
- Real Time Polymerase Chain Reaction
- URI
- Upper Respiratory tract Infections
